Compare BCE & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCE | WAT |
|---|---|---|
| Founded | 1880 | 1958 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5B | 22.5B |
| IPO Year | N/A | 1995 |
| Metric | BCE | WAT |
|---|---|---|
| Price | $25.74 | $321.68 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 19 |
| Target Price | $29.50 | ★ $394.17 |
| AVG Volume (30 Days) | ★ 3.9M | 1.3M |
| Earning Date | 02-05-2026 | 02-09-2026 |
| Dividend Yield | ★ 4.94% | N/A |
| EPS Growth | ★ 3698.16 | 0.47 |
| EPS | 4.95 | ★ 10.76 |
| Revenue | ★ $17,845,265,182.00 | $3,165,286,000.00 |
| Revenue This Year | $4.71 | $7.35 |
| Revenue Next Year | $1.24 | $6.39 |
| P/E Ratio | ★ $5.21 | $30.05 |
| Revenue Growth | 0.24 | ★ 6.99 |
| 52 Week Low | $20.28 | $275.05 |
| 52 Week High | $26.49 | $414.15 |
| Indicator | BCE | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 59.97 | 24.01 |
| Support Level | $25.44 | $305.35 |
| Resistance Level | $25.95 | $337.83 |
| Average True Range (ATR) | 0.45 | 12.09 |
| MACD | -0.05 | -7.24 |
| Stochastic Oscillator | 51.29 | 14.97 |
BCE provides wireless, broadband, television, and landline phone services in Canada. It is one of the Big Three national wireless carriers, with over 10 million customers constituting about 30% of the market. It is also the incumbent local exchange carrier—the legacy telephone provider—throughout much of the eastern half of Canada, including in the most populous Canadian provinces: Ontario and Quebec. BCE has a media segment that holds television, radio, and digital media assets. BCE licenses the Canadian rights to HBO Max and Starz.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.